CEREBRAL UPTAKE OF DRUGS IN HUMANS

Clinical and Experimental Pharmacology and Physiology - Tập 34 Số 8 - Trang 695-701 - 2007
Richard N. Upton1
1Department of Anaesthesia and Intensive Care, Royal Adelaide Hospital Adelaide, South Australia Australia

Tóm tắt

SUMMARY Drugs that target the central nervous system (CNS) are under‐represented in the pharmacopoeia because of the difficulties of overcoming passive and active defences of the blood–brain barrier (BBB). Methods have been developed in drug discovery to make decisions about whether a compound crosses the BBB. Less is known about how the rate and extent of CNS penetration of a drug affects its clinical behaviour, largely because of past difficulties in measuring the cerebral uptake of drugs in humans. Three methods for doing so are reviewed. Microdialysis is sometimes used as a clinical tool for monitoring the brain in neurointensive care and opportunistic pharmacological studies are possible. The method is relatively cheap and simple, measures free drug concentrations and is better suited to characterizing slowly changing brain drug concentrations. Measuring cerebral drug uptake using positron emission tomography imaging requires the use of short‐lived isotopes (labelled drug or labelled receptor ligand). Data with high spatial and temporal resolution can be collected, but the method requires expensive infrastructure. Jugular bulb catheters collect pure brain venous blood and are sometimes placed for neuromonitoring. Cerebral drug uptake is inferred from the arterial to cerebral venous concentration difference. The method is relatively cheap and simple and allows global brain concentrations to be estimated. It is better suited to characterizing rapidly changing brain concentrations and effects. The cerebral kinetics of a cerebro‐active drug can make substantial contributions to its clinical behaviour. For example, loperamide is a peripherally acting opioid that has little CNS effect due to the active efflux transport of loperamide from the brain back into the blood by transporters including P‐glycoprotein. The opioids alfentanil and fentanyl differ in their duration of action largely because of differences in their cerebral distribution volume rather than differences in systemic kinetics. The onset of anaesthesia of the intravenous anaesthetic propofol is governed almost completely by the kinetics of the first‐pass passage of the drug through the brain and is more affected by changes in cerebral blood flow than hepatic clearance. Continuing to exploit and develop these methods may provide new avenues to enhance the safety and efficacy of cerebro‐active drugs in clinical practice.

Từ khóa


Tài liệu tham khảo

10.1124/pr.57.2.4

10.1002/ar.b.20087

Cserr HF, 1984, Blood–brain interfaces in vertebrates: A comparative approach, Am. J. Physiol., 246, R277

10.1146/annurev.ento.45.1.151

10.1097/00008571-200111000-00012

10.1016/S1359-6446(02)02195-5

10.1016/S1359-6446(03)02827-7

10.2174/1389200003338901

10.1211/jpp.58.3.0001

10.1016/S0169-409X(00)00108-3

10.1016/S0169-409X(00)00110-1

Ungerstedt U, 1974, Functional correlates of dopamine neurotransmission, Bull. Schweiz Akad. Med. Wiss., 30, 44

10.1007/BF01405420

10.2174/1381612043384105

10.1034/j.1399-6576.2001.045003390.x

10.1046/j.1365-2125.2003.02032.x

10.1007/s00134-005-0015-3

Mindermann T, 1998, Rifampin concentrations in various compartments of the human brain: A novel method for determining drug levels in the cerebral extracellular space, Antimicrob. Agents Chemother., 42, 2626, 10.1128/AAC.42.10.2626

10.1212/WNL.44.8.1469

10.1016/0920-1211(94)90043-4

10.1016/S0006-8993(98)00572-1

10.1016/S0031-9384(99)00110-9

10.1016/1056-8719(92)90074-B

10.1002/bdd.332

10.1039/b308057a

10.1034/j.1600-0773.2002.910402.x

10.1016/S0150-9861(05)83159-1

10.1016/j.nucmedbio.2005.04.017

10.2174/1381612013396871

10.1007/s00259-002-0823-4

10.1007/s00213-005-2271-x

Roivainen A, 2004, Biodistribution and blood metabolism of 1‐11C‐methyl‐4‐piperidinyl n‐butyrate in humans: An imaging agent for in vivo assessment of butyrylcholinesterase activity with PET, J. Nucl. Med., 45, 2032

10.1124/jpet.105.089102

10.1016/j.nucmedbio.2004.06.007

10.2174/1381612043384736

10.2174/157340506776930610

10.1046/j.1365-2044.2001.01707.x

De Deyne C, 1998, Jugular bulb oximetry: Review on a cerebral monitoring technique, Acta Anaesthesiol. Belg., 49, 21

10.1097/00000542-200212000-00006

10.1172/JCI101994

10.1002/cpt19601116

10.1097/00000542-196001000-00008

10.1097/00000542-195701000-00038

10.1111/j.1365-2044.2003.03654.x

10.1046/j.1365-2044.2003.03346.x

Lu CC, 2003, Pharmacokinetics of isoflurane: Uptake in the brain, Pharmacology, 69, 102, 10.1159/000072363

10.1111/j.1365-2044.2004.03966.x

10.1023/A:1020798806704

10.1093/bja/82.6.890

10.1007/BF01061860

10.1007/BF02353624

10.1097/00000542-200006000-00012

10.1097/00000542-200010000-00033

10.1097/00000542-200508000-00018

10.1097/00004714-200102000-00001

10.1067/mcp.2000.109156

10.1016/j.pneurobio.2005.04.006

Bauer B, 2004, Pregnane X receptor up‐regulation of P‐glycoprotein expression and transport function at the blood–brain barrier, Mol. Pharmacol., 66, 413

10.1016/S0024-3205(99)00599-8

10.1146/annurev.pharmtox.43.100901.140233

Scott JC, 1987, Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation, J. Pharmacol. Exp. Ther., 240, 159

10.2165/00003088-199733030-00005

10.1097/00000542-199706000-00013

10.1093/bja/aeh261

Macintyre PE, 2001, Acute Pain Management: A Practical Guide

10.1093/bja/aeh089

10.1097/00000542-199612000-00010

Thông tin
Thông tin xuất bản

Clinical and Experimental Pharmacology and Physiology

Tập 34 Số 8

695-701

Thông tin tác giả